Zealand Pharma completes registration of capital increase

On February 1, 2021 Zealand Pharma A/S ("Zealand") reported that it has today, as part of completion of a directed issue and private placement (the "Offering"), registered with the Danish Business Authority, the capital increase of DKK 3,600,841, divided into 3,600,841 ordinary shares (the "New Shares") (Press release, Zealand Pharmaceuticals, FEB 1, 2021, View Source [SID1234576927]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the registration of the New Shares with the Danish Business Authority, Zealand’s share capital amounts to DKK 43,400,547 divided into 43,400,547 shares with a nominal value of DKK 1 each.

The New Shares rank pari passu with Zealand’s existing shares and carry the same dividend and other rights. Each New Share carries one vote at Zealand’s general meetings. Zealand only has one class of shares.

The New Shares have been issued under a temporary ISIN code and are expected to be admitted to trading on Nasdaq Copenhagen on 2 February 2021 in Zealand’s permanent ISIN code DK0060257814. The temporary ISIN code is expected to be merged with the permanent ISIN code on 3 February 2021.

The amendments to Zealand’s articles of association required by the capital increase have been registered today with the Danish Business Authority.

Managers and legal counsels:

Goldman Sachs International, Jefferies GmbH and Danske Bank A/S (the "Joint Global Coordinators") are acting as joint global coordinators and joint bookrunners in the Offering, and Bryan, Garnier & Co. and Nordea Danmark, Filial af Nordea Bank Abp, Finland are acting as co-managers in the Offering (the Joint Global Coordinators and the co-managers are jointly referred to as the "Managers"). Danske Bank A/S is acting as settlement agent for the Offering.